Tempus AI, Inc. (NASDAQ:TEM) Short Interest Update

Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) was the target of a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 8,730,000 shares, an increase of 42.2% from the December 15th total of 6,140,000 shares. Based on an average daily trading volume, of 2,340,000 shares, the short-interest ratio is presently 3.7 days. Approximately 17.8% of the company's stock are sold short.

Tempus AI Stock Down 0.6 %

NASDAQ:TEM traded down $0.21 during mid-day trading on Thursday, hitting $34.71. 2,488,269 shares of the company's stock traded hands, compared to its average volume of 4,020,976. The firm has a 50 day moving average of $47.24 and a two-hundred day moving average of $47.17. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55. Tempus AI has a 12 month low of $22.89 and a 12 month high of $79.49.

Insider Transactions at Tempus AI

In other Tempus AI news, EVP Andrew Polovin sold 51,504 shares of the company's stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $42.39, for a total value of $2,183,254.56. Following the transaction, the executive vice president now owns 246,085 shares in the company, valued at approximately $10,431,543.15. This represents a 17.31 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Bradley A. Keywell sold 395,800 shares of the stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $42.95, for a total transaction of $16,999,610.00. Following the completion of the sale, the insider now owns 16,164,449 shares of the company's stock, valued at approximately $694,263,084.55. The trade was a 2.39 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 865,041 shares of company stock valued at $35,917,673 over the last quarter.

Institutional Investors Weigh In On Tempus AI

Several hedge funds have recently modified their holdings of TEM. First Horizon Advisors Inc. bought a new stake in Tempus AI in the 3rd quarter valued at $30,000. FNY Investment Advisers LLC acquired a new position in shares of Tempus AI during the fourth quarter valued at about $67,000. Sandia Investment Management LP bought a new stake in shares of Tempus AI in the second quarter valued at about $136,000. Vestor Capital LLC acquired a new stake in Tempus AI during the third quarter worth about $153,000. Finally, Stifel Financial Corp bought a new position in Tempus AI during the third quarter valued at about $218,000. 24.22% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts recently issued reports on TEM shares. Wolfe Research assumed coverage on Tempus AI in a report on Friday, December 13th. They set an "outperform" rating and a $60.00 price objective for the company. Needham & Company LLC reiterated a "buy" rating and set a $56.00 price target on shares of Tempus AI in a report on Tuesday. Stifel Nicolaus downgraded Tempus AI from a "buy" rating to a "hold" rating and increased their price objective for the stock from $45.00 to $65.00 in a report on Monday, November 11th. Bank of America lifted their target price on shares of Tempus AI from $52.00 to $54.00 and gave the company a "neutral" rating in a research note on Friday, December 13th. Finally, Guggenheim initiated coverage on shares of Tempus AI in a research note on Monday, December 9th. They issued a "buy" rating and a $74.00 price objective for the company. Three analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $56.36.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.